预测营养指数对接受纳武利尤单抗单药治疗的胃癌或胃食管结合部癌患者的影响。
Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy.
机构信息
Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan.
Department of Gastrointestinal Surgery, Kanagawa Cancer Centre, Yokohama, Japan;
出版信息
In Vivo. 2021 Jan-Feb;35(1):563-569. doi: 10.21873/invivo.12292.
Abstract
BACKGROUND/AIM: We hypothesised that the prognostic nutrition index (PNI) is useful for evaluating host immunity and response to immune checkpoint inhibitors. We investigated the effect of PNI on nivolumab monotherapy efficacy in advanced or recurrent gastric cancer (GC) or gastro-oesophageal junction cancer (GOC) patients.
PATIENTS AND METHODS
We retrospectively examined 110 patients, divided them into a high-PNI group and a low-PNI group, and compared treatment efficacy, adverse events (AEs), and survival between the groups.
RESULTS
Median overall survival (OS) was significantly longer in the high-PNI group than in the low-PNI group (205 vs. 109 days; p<0.001). Multivariate analysis revealed that low PNI was an independent risk factor for OS (hazard ratio=2.398; 95% confidence interval=1.384-4.154; p=0.002). The overall response rate and frequency of AEs were not significantly different between the groups.
CONCLUSION
PNI could be a useful prognostic factor in GC or GOC patients undergoing nivolumab monotherapy.
摘要
背景/目的：我们假设预后营养指数（PNI）可用于评估宿主免疫和对免疫检查点抑制剂的反应。我们研究了 PNI 对晚期或复发性胃癌（GC）或胃食管交界处癌（GOC）患者接受纳武利尤单抗单药治疗疗效的影响。
患者和方法
我们回顾性检查了 110 名患者，将其分为高 PNI 组和低 PNI 组，并比较了两组的治疗疗效、不良事件（AE）和生存情况。
结果
高 PNI 组的中位总生存期（OS）明显长于低 PNI 组（205 天 vs. 109 天；p<0.001）。多因素分析显示，低 PNI 是 OS 的独立危险因素（风险比=2.398；95%置信区间=1.384-4.154；p=0.002）。两组的总缓解率和 AE 发生率无显著差异。
结论
PNI 可能是 GC 或 GOC 患者接受纳武利尤单抗单药治疗的一个有用的预后因素。
相似文献
1
Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy.
In Vivo. 2021 Jan-Feb;35(1):563-569. doi: 10.21873/invivo.12292.
2
Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol. 2024 Jun 20;15:1382417. doi: 10.3389/fimmu.2024.1382417. eCollection 2024.
3
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11.
4
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
5
Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy.
Chonnam Med J. 2022 Jan;58(1):24-28. doi: 10.4068/cmj.2022.58.1.24. Epub 2022 Jan 25.
6
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
7
Using the preoperative prognostic nutritional index as a predictive factor for non-cancer-related death in post-curative resection gastric cancer patients: a retrospective cohort study.
BMC Gastroenterol. 2020 Aug 5;20(1):256. doi: 10.1186/s12876-020-01402-z.
8
Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
Surg Today. 2020 Nov;50(11):1486-1495. doi: 10.1007/s00595-020-02048-w. Epub 2020 Jun 15.
9
Significance of Preoperative Prognostic Nutritional Index in the Perioperative Management of Gastric Cancer.
J Gastrointest Surg. 2022 Mar;26(3):558-569. doi: 10.1007/s11605-021-05168-x. Epub 2021 Nov 1.
10
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y.
引用本文的文献
1
Prognostic nutrition index reveals LAG3 in cytotoxic CD8+ T cells and MHC class II in gastric cancer cells.
Cancer Immunol Immunother. 2025 Apr 19;74(6):176. doi: 10.1007/s00262-025-04037-9.
2
Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol. 2024 Jun 20;15:1382417. doi: 10.3389/fimmu.2024.1382417. eCollection 2024.
3
The prognostic value of preoperative laboratory data indicators in patients with esophageal carcinoma: An observational study.
Medicine (Baltimore). 2024 Jun 14;103(24):e38477. doi: 10.1097/MD.0000000000038477.
4
Albumin‑bilirubin grade is an independent prognostic factor for small lung cell cancer.
Mol Clin Oncol. 2023 Dec 15;20(2):12. doi: 10.3892/mco.2023.2710. eCollection 2024 Feb.
5
Preoperative Osteopenia as Risk Factor for Death from Other Diseases After Gastrectomy in Elderly Patients.
In Vivo. 2023 Nov-Dec;37(6):2662-2668. doi: 10.21873/invivo.13375.
6
Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors.
Front Immunol. 2023 Jul 21;14:1219929. doi: 10.3389/fimmu.2023.1219929. eCollection 2023.
7
Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
World J Surg Oncol. 2023 Jul 7;21(1):198. doi: 10.1186/s12957-023-03077-8.
8
Preoperative prognostic nutritional index predicts short-term complications after radical resection of distal cholangiocarcinoma.
Front Surg. 2023 Jan 10;9:1091534. doi: 10.3389/fsurg.2022.1091534. eCollection 2022.
9
Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Front Nutr. 2022 Jul 22;9:823087. doi: 10.3389/fnut.2022.823087. eCollection 2022.
10
The Modified Glasgow Prognostic Score and Prognostic Nutritional Index as Prognostic Markers in Patients With Metastatic Breast Cancer Treated With Eribulin.
In Vivo. 2022 Jul-Aug;36(4):1854-1859. doi: 10.21873/invivo.12903.
本文引用的文献
1
Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
Surg Today. 2020 Nov;50(11):1486-1495. doi: 10.1007/s00595-020-02048-w. Epub 2020 Jun 15.
2
Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer.
Lung Cancer Manag. 2020 Apr 24;9(2):LMT31. doi: 10.2217/lmt-2020-0008.
3
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20.
4
Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab.
J Thorac Dis. 2019 Sep;11(9):3757-3768. doi: 10.21037/jtd.2019.09.29.
5
From cachexia to obesity: the role of host metabolism in cancer immunotherapy.
Curr Opin Support Palliat Care. 2019 Dec;13(4):305-310. doi: 10.1097/SPC.0000000000000457.
6
The prognostic nutritional index is prognostic factor of gynecological cancer: A systematic review and meta-analysis.
Int J Surg. 2019 Jul;67:79-86. doi: 10.1016/j.ijsu.2019.05.018. Epub 2019 Jun 8.
7
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
J Clin Med. 2019 Apr 3;8(4):450. doi: 10.3390/jcm8040450.
8
Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: A systematic review and meta-analysis.
Int J Biol Markers. 2018 Nov;33(4):372-378. doi: 10.1177/1724600818799876. Epub 2018 Oct 3.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
Clin Cancer Res. 2018 Dec 1;24(23):5841-5849. doi: 10.1158/1078-0432.CCR-18-0415. Epub 2018 Jun 11.
Zotero 插件